KalVista Pharmaceuticals, Inc. (KALV)

20.19 +0.29 (+1.46%) USD  |  NASDAQ  |  Apr 06, 16:00
20.16 -0.03 (-0.15%) After-Hours: 05:04
More

KalVista Pharmaceuticals SG&A Expense (TTM) : 191.34M for Dec. 31, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for KALV.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Intellia Therapeutics, Inc. 119.80M
Recursion Pharmaceuticals, Inc. 176.59M
Tango Therapeutics, Inc. 41.51M
Modular Medical, Inc. 6.786M
Iovance Biotherapeutics, Inc. 152.58M